The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.50
Bid: 36.00
Ask: 37.00
Change: 7.50 (25.86%)
Spread: 1.00 (2.778%)
Open: 29.00
High: 36.50
Low: 29.00
Prev. Close: 29.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

Thu, 28th Mar 2024 13:44

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Northamber PLC - London-based distributor of audio-visual and information technology equipment - Revenue in the six months to December 31 falls to GBP29.2 million from GBP33.6 million while pretax loss widens to GBP413,000 from GBP250,000. Notes broader macro-economic factors and market sentiment impacted the industry. Explains softer demand resulted in slower stock turns, leading to an increase in stock at period end of GBP10.3 million compared to GBP9.6 million. Proposes unchanged interim dividend of 0.3p. Remains cautious short term as the UK market continues to be challenging but notes industry analysts expect a recovery through 2024 in demand levels as business confidence hopefully returns.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Announces business update. Highlights positive engagement with a number of potential new customers, including two OEM vendors which, following an extensive evaluation of Ethernity's Universal Edge Platform have indicated an interest to adopt and launch the product to their customer base. Talks continue with these two vendors on potential contracts that could lead to significant business for Ethernity. Estimates the contracts could contribute between USD2.2 million and USD3 million to revenue in 2024, plus "significantly higher revenues in 2025 and beyond".

----------

Rurelec PLC - gas producer focused on operations in Latin America - Reports pretax profit in the six months to December 31 of GBP559,000, swinging from pretax loss of GBP2.9 million. Earnings per share total 0.09 pence compared to LPS of 0.51p. Administration expenses decline to GBP0.31 million from GBP0.48 million. Explains the board's strategy is now to seek a reverse takeover "through which to generate value for our shareholders, and to give the company access to further resource thereby allowing more time to achieve a sale of the two Siemens 701 turbines." Adds: "While we continue to hold discussions with credible potential purchasers of the turbines, these initiatives are at an early stage following the withdrawal of counterparties to our earlier discussions for reasons unconnected with Rurelec. The timing of any potential sale of the turbines remains highly uncertain owing to the limited demand and infrequent occurrence of projects into which the turbines could be injected."

----------

Sareum Holdings PLC - Reports pretax loss in the six months to December 31 widens to GBP3.3 million from GBP1.7 million. No revenue was disclosed as per the year prior. Operating expenses rise to GBP2.5 million from GBP1.7 million. Basic and diluted loss per share totals 3.6 pence compared to 2.1p. Further, raises GBP1.5 million via placing, subscription and retail offer at 10p per share. Intends to use proceeds to complete Phase 1a clinical studies on its SDC-1801 TYK2/JAK1 inhibitor and, together with the receipt of an anticipated R&D tax credit of GBP0.7 million for general working capital purposes.

----------

Team PLC - wealth, asset management and complementary financial services group - Plans to raise GBP1.1 million via GBP700,000 placing and GBP400,000 subscription at 20 pence per share. Explains funds will be used for the financing of acquisitions and deferred consideration, as well as providing cash for working capital and general corporate purposes. Notes fundraise is supported by existing and new shareholders. Further, intends to raise GBP750,000 via retail offer.

----------

First Tin PLC - London-based tin development company focused on advanced, low-capital expenditure projects in Germany and Australia - Reports pretax loss in 2023 narrows to GBP2.3 million from GBP3.2 million the year prior. Diluted loss per share totals 0.85 pence compared to 1.40p. Says 2024 is shaping up to be "another busy year" with the definitive feasibility study at the Taronga asset soon to be completed and the finalisation of the mineral resource estimate at the Tellerhauser asset in the third quarter. "Our outlook for the tin market remains bullish, and we are already seeing strong signs of tin price recovery. The demand for tin remains ever-present as tin becomes increasingly recognised as crucial to the global energy transition and digital revolution," company states.

----------

Home REIT PLC - London-based real estate company, which focuses on investing in accommodation for homeless people - Sells 63 properties for GBP6.1 million, around 1.8% of the company's portfolio by value. Notes gross proceeds from the sales are GBP0.5 million, below the draft August 2023 values. Explains the majority of the properties sold are below portfolio average lot size which may cause a greater percentage variation when comparing sale price to the August draft valuation. Since August 2023, the company has completed on the sale of 451 properties and exchanged on a further 257 properties. Sale proceeds will be used to reduce borrowings and provide working capital.

----------

React Group PLC - Birmingham, England-based cleaning, hygiene and decontamination firm - Issues trading statement ahead of Thursday's annual general meeting. Reports that revenue for the first five months of the current financial year ending September is ahead of the same period in last year. Says: "Each division has performed well and the group continues to benefit from cross selling opportunities which not only enhance our offering but also contribute to the organic growth. It is particularly pleasing to deliver revenue growth in a challenging market environment where our customers are always striving for the best in class service that we offer."

----------

Westminster Group PLC - London-based provider of security services, for sensitive places such as ports, airports and commercial buildings - Revenue in the six months to December 31 falls to GBP2.9 million from GBP3.5 million the year before, while pretax loss widens to GBP1.9 million from GBP287,000. Loss per share totals 0.58 pence compared to 0.09p. Chief Executive Peter Fowler says: "We continue to battle against probably one of the worst world economic and political backgrounds in recent times." Explains revenue fell largely due to the economic climate delaying some capital-intensive orders. Fowler adds: "We started 2024 with an order book of GBP1.1 million and recurring revenues of GBP3.7 million which provide a healthy start for the year. With DRC expected to come on stream and other potential projects in the pipeline we believe the months and year ahead will be transformative for the group."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.